Article in EMBO molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
12 authors.
Qianqian Li *Guangdong Provincial Engineering Research Center of Molecular Imaging, The Fifth Affiliated Hospital of Sun Yat-sen University, 519000, Zhuhai, Guangdong, China.ORCID http://orcid.org/0009-0004-6919-5050
Yubo Zhang *Guangdong Provincial Engineering Research Center of Molecular Imaging, The Fifth Affiliated Hospital of Sun Yat-sen University, 519000, Zhuhai, Guangdong, China.
Hui Luo *Guangdong Provincial Engineering Research Center of Molecular Imaging, The Fifth Affiliated Hospital of Sun Yat-sen University, 519000, Zhuhai, Guangdong, China.ORCID http://orcid.org/0000-0003-2527-0237
Yongjian Wu *Guangdong Provincial Engineering Research Center of Molecular Imaging, The Fifth Affiliated Hospital of Sun Yat-sen University, 519000, Zhuhai, Guangdong, China.
Jingbo QinGuangdong Provincial Engineering Research Center of Molecular Imaging, The Fifth Affiliated Hospital of Sun Yat-sen University, 519000, Zhuhai, Guangdong, China.
Lijie WangGuangdong Provincial Engineering Research Center of Molecular Imaging, The Fifth Affiliated Hospital of Sun Yat-sen University, 519000, Zhuhai, Guangdong, China.
Qianqian ZhangGuangdong Provincial Engineering Research Center of Molecular Imaging, The Fifth Affiliated Hospital of Sun Yat-sen University, 519000, Zhuhai, Guangdong, China.
Ting YuGuangdong Provincial Engineering Research Center of Molecular Imaging, The Fifth Affiliated Hospital of Sun Yat-sen University, 519000, Zhuhai, Guangdong, China.
Xi HuangGuangdong Provincial Engineering Research Center of Molecular Imaging, The Fifth Affiliated Hospital of Sun Yat-sen University, 519000, Zhuhai, Guangdong, China. huangxi6@mail.sysu.edu.cn.ORCID http://orcid.org/0000-0002-4829-8390
Shuang GuoGuangdong Provincial Engineering Research Center of Molecular Imaging, The Fifth Affiliated Hospital of Sun Yat-sen University, 519000, Zhuhai, Guangdong, China. guoshuang0317@hrbmu.edu.cn.ORCID http://orcid.org/0000-0003-0309-8173
Bingfan XieDepartment of Gynecology, The Fifth Affiliated Hospital of Sun Yat-sen University, 519000, Zhuhai, Guangdong, China. xiebf3@mail.sysu.edu.cn.ORCID http://orcid.org/0009-0005-7369-1310
MOST | National Natural Science Foundation of China (NSFC) 32400531MOST | National Natural Science Foundation of China (NSFC) 82103443MOST | National Natural Science Foundation of China (NSFC) 82322008
6 · The paper itself
Abstract
Ascites, a hallmark of advanced ovarian cancer, severely impairs patient quality of life and contributes to therapeutic resistance. Current management strategies remain primarily palliative, highlighting the urgent need to elucidate the underlying mechanisms. Although TREM2
Indexed as
AscitesCapillary PermeabilityMembrane GlycoproteinsOvarian NeoplasmsPhosphoproteinsReceptors, ImmunologicRNA-Binding ProteinsAnimalsAntigens, CDCell Line, TumorEndothelial CellsFemaleHumansMiceNitric Oxide Synthase Type IIINucleolinAntigens, CDMembrane GlycoproteinsNitric Oxide Synthase Type IIINucleolinPhosphoproteinsProto-Oncogene Proteins c-aktReceptors, ImmunologicRNA-Binding ProteinsTREM2 protein, human
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Soluble TREM2 engages cell-surface nucleolin to drive vascular permeability and malignant ascites in ovarian cancer. · full record | OpenQuestion